Trial · NCT07895875
Clinical Hypnosis Versus Guided Imagery for Dissociative Symptoms in Adults
NCT07895875, Not applicable, Not yet recruiting, University of Rome Foro Italico
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Clinical Hypnosis Versus Guided Imagery for Dissociative Symptoms in Adults. Trials, record NCT07895875. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07895875
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Clinical Hypnosis Versus Guided Imagery for Dissociative Symptoms in Adults
- NCT number
- NCT07895875
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 160 participants, estimated
- Lead sponsor
- University of Rome Foro Italico
- Conditions
- Dissociative Symptoms
- Interventions
- Clinical Hypnosis, Non-Hypnotic Guided Imagery
- First posted
- 2026-10-26
- Last updated
- 2026-10-26
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Dissociative Symptom Severity (DES-II Total Score) Copia | 7 ± 3 days after the fourth intervention session (post-treatment). | Dissociative symptom severity will be assessed using the Dissociative Experiences Scale-II (DES-II), a 28-item self-report questionnaire measuring the frequency of dissociative experiences. The total score is calculated as the mean of the 28 item scores and ranges from 0 to 100, with higher scores indicating greater dissociative symptom severity. The primary endpoint is the DES-II total score at post-treatment. The primary treatment effect will be estimated as the adjusted between-group difference in post-treatment DES-II scores, controlling for baseline DES-II. |
| Secondary | Dissociative Symptom Severity at 3-Month Follow-up (DES-II) | 3 months after Session 4 (±14 days) | Dissociative symptom severity will be assessed using the Dissociative Experiences Scale-II (DES-II), a 28-item self-report measure. The total score ranges from 0 to 100, with higher scores indicating greater dissociative symptom severity. This secondary endpoint will evaluate maintenance of treatment effects at 3-month follow-up. |
| Secondary | Dissociative Symptom Severity at 6-Month Follow-up (DES-II) | 6 months after Session 4 (±14 days). | Dissociative symptom severity will be assessed using the Dissociative Experiences Scale-II (DES-II), a 28-item self-report measure. The total score ranges from 0 to 100, with higher scores indicating greater dissociative symptom severity. This secondary endpoint will evaluate maintenance of treatment effects at 6-month follow-up. |
| Secondary | Global Psychological Distress (SCL-90-R Global Severity Index) | Baseline and 7 ± 3 days after Session 4 (post-treatment). | Global psychological distress will be assessed using the Global Severity Index (GSI) of the Symptom Checklist-90-Revised (SCL-90-R). The GSI summarizes overall psychological symptom distress, with higher scores indicating greater severity. Post-treatment scores will be compared between groups, adjusting for baseline values. |
| Secondary | PTSD Symptom Severity (CAPS-5 Total Score) | Baseline and 7 ± 3 days after Session 4 (post-treatment). | PTSD symptom severity will be assessed using the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5), restricted to participants meeting DSM-5 Criterion A for traumatic exposure at baseline. The total symptom severity score is calculated by summing the severity ratings of the 20 DSM-5 PTSD symptoms, ranging from 0 to 80, with higher scores indicating greater symptom severity. The same index traumatic event will be used at baseline and post-treatment. |
| Secondary | Anxiety Symptom Severity (GAD-7 Total Score) | Baseline and 7 ± 3 days after Session 4 (post-treatment). | Anxiety symptom severity will be assessed using the Generalized Anxiety Disorder-7 (GAD-7), a seven-item self-report questionnaire measuring symptoms over the preceding two weeks. Total scores range from 0 to 21, with higher scores indicating greater anxiety severity. Post-treatment scores will be compared between groups, adjusting for baseline values. |
| Secondary | Depressive Symptom Severity (PHQ-9 Total Score) | Baseline and 7 ± 3 days after Session 4 (post-treatment). | Depressive symptom severity will be assessed using the Patient Health Questionnaire-9 (PHQ-9), a nine-item self-report questionnaire measuring depressive symptoms over the preceding two weeks. Total scores range from 0 to 27, with higher scores indicating greater depressive symptom severity. Post-treatment scores will be compared between groups, adjusting for baseline values. |
| Secondary | Quality of Life (WHOQOL-BREF) | Baseline and 7 ± 3 days after Session 4 (post-treatment). | Quality of life will be assessed using the World Health Organization Quality of Life-BREF (WHOQOL-BREF), a 26-item self-report questionnaire evaluating four domains: physical health, psychological health, social relationships, and environment. Domain scores will be calculated according to standard WHO scoring procedures, with higher scores indicating better quality of life. The four domain scores will be analyzed separately, without calculating an overall total score. Post-treatment scores will be compared between treatment groups, adjusting for the corresponding baseline values. |
| Other | Sense of Agency (SoAS) - Exploratory Process Measure | Baseline; after Session 2 and before Session 3; and 7 ± 3 days after Session 4 (post-treatment). | Sense of agency will be assessed using the Italian version of the Sense of Agency Scale (SoAS). The scale measures individuals' subjective experience of control over their actions and experiences. Sense of agency is a prespecified exploratory process measure. The study will examine whether differences in sense of agency between treatment groups at the intermediate assessment, adjusted for baseline SoAS, are associated with subsequent differences in dissociative symptom severity at post-treatment. Exploratory mediation analyses will investigate this potential relationship without assuming that a causal mechanism has been established. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07895875
GET https://conductscience.org/api/trials/v1/NCT07895875/registered